Heck I, Niederle N
Klin Wochenschr. 1983 Sep 15;61(18):923-7. doi: 10.1007/BF01537533.
In 43 patients with inoperable bronchogenic carcinoma--32 small cell and 11 squamous or large cell--Angiotensin-Converting-Enzyme (ACE) activity in serum was determined before and every 3-5 weeks during cytotoxic chemotherapy. ACE-activity prior to therapy was 10.7 U +/- 1.17 SE as compared to the normal values 20.4 U +/- 1.8 SE which was statistically significant (p less than 0.01). There was no significant difference between the basal values of patients with small cell and not small cell-carcinoma of the lung. Only for patients with small cell-carcinoma of the lung a significant rise in ACE-activity could be obtained. Mean values of these patients reached normal levels in case they had complete remission, which was achieved in the limited disease group in 82% of patients. The present data suggest, that ACE-activities in serum correspond well to the clinical course in patients with small cell carcinoma of the lung. The decision on the individual mode of therapy may thus become more substantiated by serial determinations of ACE in the course of treatment.
对43例无法手术的支气管源性癌患者（32例小细胞癌和11例鳞状或大细胞癌），在细胞毒性化疗前及化疗期间每3 - 5周测定血清中的血管紧张素转换酶（ACE）活性。治疗前ACE活性为10.7 U±1.17 SE，而正常值为20.4 U±1.8 SE，差异有统计学意义（p＜0.01）。肺小细胞癌患者和非小细胞癌患者的基础值无显著差异。仅肺小细胞癌患者的ACE活性有显著升高。这些患者若完全缓解，其平均值可达到正常水平，在局限性疾病组中82%的患者实现了完全缓解。目前的数据表明，血清中的ACE活性与肺小细胞癌患者的临床病程密切相关。因此，在治疗过程中通过连续测定ACE，对个体治疗方式的决策可能会更有依据。
